Multiple Sclerosis

Actress Jamie Lynn Sigler discussed how patient education, treatment adherence, and self-advocacy have shaped her approach to living with multiple sclerosis at the 2026 CMSC Annual Meeting.

Carrie Hersh, DO, MSc, FAAN, president of the Consortium of Multiple Sclerosis Centers, discussed key sessions presented on disability progression, emerging biomarkers, and the shift toward comprehensive, patient-centered MS care.

Ahmed Obeidat, MD, PhD, associate professor of neurology at the Medical College of Wisconsin, talked about the need to rethink multiple sclerosis clinical trial design by recognizing immune cells’ potential neuroprotective roles.

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC, director of the multiple sclerosis research unit at Ottawa Hospital, outlined how research-integrated multiple sclerosis care can refine treatment strategies in clinical practice.

At CMSC 2026, the assistant professor of neurology at NYU Grossman School of Medicine talked about how optical coherence tomography contributes to the updated 2024 McDonald criteria for multiple sclerosis. [WATCH TIME: 4 minutes]

A cross-sectional survey of 4181 NARCOMS Registry participants found that only 7.4% had ever used semaglutide or tirzepatide, despite 40% meeting FDA-approved indications for the drugs.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 20 minutes]

The first randomized, double-blind trial directly comparing the 2 anti-CD20 agents showed rituximab met the prespecified noninferiority criterion on MRI suppression, with a similar serious adverse event profile and a substantially lower cost.

At CMSC 2026, the associate professor of neurology at the Medical College of Wisconsin discussed the need to reconsider clinical trial paradigms by recognizing the role of immune cells in MS. [WATCH TIME: 6 minutes]

TG Therapeutics has indicated it plans to submit a supplemental BLA to the FDA in the second half of 2026, seeking approval for the consolidated initiation regimen of ublituximab-xiiy.

At CMSC 2026, the director of the multiple sclerosis research unit at Ottawa Hospital discussed how integrating clinical research into MS practice enhances clinician expertise. [WATCH TIME: 5 minutes]

The 510(k) clearance was supported by a 3-study, 159-patient registrational program showing a 45.5% increase in response rate vs physical therapy alone, and includes Medicare coverage at launch.

Tom Fuchs, MD, PhD, postdoctoral researcher at the MS Center at Amsterdam University Medical Center, shared his reaction to the European Commission's approval of tolebrutinib for nonrelapsing secondary progressive MS.

Jens Kuhle, MD, PhD, head of the Multiple Sclerosis Centre at University Hospital Basel, discusses the EU approval of tolebrutinib for nonrelapsing SPMS and its implications for treating disability progression.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Grace Gombolay, MD; and Varun Kannan, MD. [LISTEN TIME: 25 minutes]

The European Commission has approved Cenrifki (tolebrutinib) for nrSPMS without relapses in the last two years, a milestone that arrives despite the drug's failed US submission and a regulatory pathway that has been anything but linear.

The professor of neurology at UT Southwestern Medical Center discussed the Octave Multiple Sclerosis Disease Activity Test as a complementary tool to MRI and clinical assessment in MS. [WATCH TIME: 6 minutes]

FDA’s clearance for PTD802, a first-in-class GPR17 antagonist designed to promote remyelination, enables initiation of a first-in-human phase 1 study in healthy volunteers and advances a novel regenerative approach for multiple sclerosis.

Neurologists Sarah Simmons, MD, PhD, and Fatma Inanici, MD, PhD, discuss how the combination of noninvasive cervical spinal cord stimulation with exercise therapy can improve upper extremity function in people with MS.

The senior vice president for research at the Kessler Foundation discussed findings showing associations between reductions in neurofilament light chain and gains in cognitive processing speed, verbal memory, and visual memory in patients with early relapsing multiple sclerosis treated with ozanimod. [WATCH TIME: 3 minutes]

The new president of Consortium of Multiple Sclerosis Centers (CMSC) discussed key themes in multiple sclerosis care presented at the 2026 CMSC Annual Meeting. [WATCH TIME: 11 minutes]

Daniel Vitt, PhD, chief executive officer of Immunic, discussed the dual mechanism of vidofludimus calcium, ongoing phase 3 ENSURE trials in relapsing MS, and phase 2 CALLIPER findings suggesting potential neuroprotective effects in progressive MS.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 5, 2026.

The professor of neurology at the University of Colorado discussed evidence from DISCOMS and other trials on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis. [WATCH TIME: 8 minutes]

At CMSC 2026, the neuroimmunologist and director at OhioHealth MS Center, discussed results from the phase 3 FENhance 1 and 2 studies, highlighting significant reductions in relapse rates and robust MRI outcomes. [WATCH TIME: 3 minutes]